Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Trial of Extended Induction Epratuzumab (Anti-CD22 Monoclonal Antibody) (CALGB IND XXXXX) Plus Rituximab in Previously Untreated Follicular Non-Hodgkin's Lymphoma (NHL).

Next Previous
X
Search
Trial Profile

A Phase II Trial of Extended Induction Epratuzumab (Anti-CD22 Monoclonal Antibody) (CALGB IND XXXXX) Plus Rituximab in Previously Untreated Follicular Non-Hodgkin's Lymphoma (NHL).

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Epratuzumab (Primary) ; Fludeoxyglucose F-18; Rituximab
  • Indications Follicular lymphoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 31 May 2020 Results establishing if BMB add value in assessing response or identify distinct progression free (PFS) or overall survival (OS) outcomes in a large, multicenter, multi-trial cohort presented at the 56th Annual Meeting of the American Society of Clinical Oncology
    • 06 Dec 2016 Pooled retrospective analysis (n=174) of this trial and two other trials (see NCT00117975 and NCT01145495) evaulating effects of early progression of disease was presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 08 Dec 2015 Pooled exploratory analysis (n=241) of 5 studies including data from this study and 4 other trials (see CTP 700006652, 700009482, 700057042, 70059082) were presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top